NasdaqGM:AGLE

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic and cancer diseases.


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has Aeglea BioTherapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AGLE's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-2.6%

AGLE

-2.8%

US Biotechs

-0.04%

US Market


1 Year Return

-13.4%

AGLE

30.6%

US Biotechs

17.1%

US Market

Return vs Industry: AGLE underperformed the US Biotechs industry which returned 30.6% over the past year.

Return vs Market: AGLE underperformed the US Market which returned 17.1% over the past year.


Shareholder returns

AGLEIndustryMarket
7 Day-2.6%-2.8%-0.04%
30 Day-15.3%-4.1%5.1%
90 Day-5.2%4.6%19.5%
1 Year-13.4%-13.4%32.7%30.6%19.6%17.1%
3 Year132.0%132.0%31.0%24.8%42.5%33.3%
5 Yearn/a4.5%-2.9%75.1%56.2%

Price Volatility Vs. Market

How volatile is Aeglea BioTherapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Aeglea BioTherapeutics undervalued compared to its fair value and its price relative to the market?

1.98x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate AGLE's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate AGLE's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: AGLE is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: AGLE is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AGLE's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AGLE is good value based on its PB Ratio (2x) compared to the US Biotechs industry average (3.4x).


Next Steps

Future Growth

How is Aeglea BioTherapeutics forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

8.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AGLE is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AGLE is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AGLE is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AGLE is forecast to have no revenue next year.

High Growth Revenue: AGLE is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: AGLE is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Aeglea BioTherapeutics performed over the past 5 years?

-40.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AGLE is currently unprofitable.

Growing Profit Margin: AGLE is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AGLE is unprofitable, and losses have increased over the past 5 years at a rate of 40.3% per year.

Accelerating Growth: Unable to compare AGLE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AGLE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (1.8%).


Return on Equity

High ROE: AGLE has a negative Return on Equity (-54.65%), as it is currently unprofitable.


Next Steps

Financial Health

How is Aeglea BioTherapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: AGLE's short term assets ($161.9M) exceed its short term liabilities ($15.9M).

Long Term Liabilities: AGLE's short term assets ($161.9M) exceed its long term liabilities ($4.8M).


Debt to Equity History and Analysis

Debt Level: AGLE is debt free.

Reducing Debt: AGLE has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AGLE has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: AGLE has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 38.5% each year.


Next Steps

Dividend

What is Aeglea BioTherapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AGLE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AGLE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AGLE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AGLE's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AGLE's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.1yrs

Average management tenure


CEO

Anthony Quinn (58 yo)

3.08yrs

Tenure

US$2,482,776

Compensation

Dr. Anthony G. Quinn, M.B Ch.B., Ph.D., FRCP, has been President and Chief Executive Officer of Aeglea BioTherapeutics, Inc. since July 19, 2018 and its Director since 2016. Dr. Quinn has served as a Direc ...


CEO Compensation Analysis

Compensation vs Market: Anthony's total compensation ($USD2.48M) is about average for companies of similar size in the US market ($USD2.03M).

Compensation vs Earnings: Anthony's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Anthony Quinn
President3.08yrsUS$2.48m1.21%
$ 3.6m
Charles York
CFO & VP4.92yrsUS$1.09m0.11%
$ 342.2k
Leslie Sloan
Chief Operating Officer3yrsUS$1.15mno data
Joey Perrone
Senior Director of Finance & Investor Relationsno datano datano data
Kelly Boothe
Director of Corporate Communicationsno datano datano data
Eugene Sackett
Vice President of Human Resourcesno datano datano data
Ravi Rao
Medical Advisor0.75yrno datano data
Michael Hanley
Chief Commercial Officer0.75yrno datano data
Eric Bradford
Chief Development Officerno datano datano data
Scott Rowlinson
Vice President of Research6.5yrsUS$607.53kno data
F. Dorr
Executive Officer3.33yrsno datano data

3.1yrs

Average Tenure

52yo

Average Age

Experienced Management: AGLE's management team is considered experienced (3.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Anthony Quinn
President3.08yrsUS$2.48m1.21%
$ 3.6m
Daniel Von Hoff
Member of Scientific Advisory Board3.92yrsno datano data
Russell Cox
Independent Chairman of the Board1.58yrsUS$129.67k0.016%
$ 47.3k
Ivana Magovcevic-Liebisch
Independent Director2.42yrsUS$97.81kno data
Matthew Vander Heiden
Member of Scientific Advisory Board3.92yrsno datano data
Armen Shanafelt
Independent Director6.67yrsUS$91.94kno data
Keith Flaherty
Member of Scientific Advisory Board3.92yrsno datano data
Sandesh Mahatme
Independent Director5.17yrsUS$106.31kno data
Arthur Frankel
Member of Scientific Advisory Board3.92yrsno datano data
Wayne Klohs
Member of Scientific Advisory Board3.92yrsno datano data
V. Lawlis
Independent Director2.08yrsUS$93.81kno data

3.9yrs

Average Tenure

57.5yo

Average Age

Experienced Board: AGLE's board of directors are considered experienced (3.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 54.4%.


Top Shareholders

Company Information

Aeglea BioTherapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Aeglea BioTherapeutics, Inc.
  • Ticker: AGLE
  • Exchange: NasdaqGM
  • Founded: 2013
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$301.049m
  • Shares outstanding: 44.60m
  • Website: https://www.aegleabio.com

Number of Employees


Location

  • Aeglea BioTherapeutics, Inc.
  • 805 Las Cimas Parkway
  • Suite 100
  • Austin
  • Texas
  • 78746
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AGLENasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDApr 2016

Biography

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic and cancer diseases. The company’s lead ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/13 00:32
End of Day Share Price2020/08/12 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.